• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种新型循环 miRNA 标志物,用于非小细胞肺癌的早期诊断和预后预测。

A novel circulating miRNA-based signature for the early diagnosis and prognosis prediction of non-small-cell lung cancer.

机构信息

Department of Thoracic Surgery, The Affiliated Hospital of Medical School of Ningbo University, Ningbo, China.

Department of Preventive Health Care, The Affiliated Hospital of Medical School of Ningbo University, Ningbo, China.

出版信息

J Clin Lab Anal. 2020 Nov;34(11):e23505. doi: 10.1002/jcla.23505. Epub 2020 Aug 9.

DOI:10.1002/jcla.23505
PMID:33463758
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7676218/
Abstract

BACKGROUND

Non-small-cell lung cancer (NSCLC) is a significant public health issue worldwide. The aim of our study was to develop a serum miRNA-based molecular signature for the early detection and prognosis prediction of NSCLC.

METHODS

The significantly altered circulating miRNAs were profiled in GSE24709. The top ten upregulated miRNAs were miR-432, miR-942, miR-29c-5p, miR-601, miR-613, miR-520d-3p, miR-1261, miR-132-5p, miR-302b, and miR-154-5p, while the top ten downregulated miRNAs were miR-562, miR-18b, miR-9-3p, miR-154-3p, miR-20b, miR-18a, miR-487a, miR-20a, miR-103, and miR-144. Then, the top four upregulated serum miRNAs (miR-432, miR-942, miR-29c-5p, and miR-601) were validated by real-time quantitative PCR. The clinical significance of two candidate serum miRNAs, miR-942 and miR-601, was further explored.

RESULTS

Our results showed that the expression levels of serum miR-942 and serum miR-601 were significantly upregulated in NSCLC. In addition, serum miR-942 and serum miR-601 showed better performance than CEA, CYFRA21-1, and SCCA for early diagnosis of NSCLC. Combining serum miR-942 and serum miR-601 enhanced the efficacy of detecting early-stage NSCLC. Moreover, high serum miR-942 and serum miR-601 were both associated with adverse clinical variables and poor survival. The NSCLC patients with simultaneously high serum miR-942 and serum miR-601 suffered worst clinical outcome, while those with simultaneously low serum miR-942 and serum miR-601 had most favorable outcome. The multivariate analysis showed that serum miR-942 and serum miR-601 were independent prognostic factors for NSCLC.

CONCLUSIONS

Taken together, serum miR-942 and serum miR-601 might serve as a promising molecular signature for the early detection and prognosis prediction of NSCLC.

摘要

背景

非小细胞肺癌(NSCLC)是全球范围内的重大公共卫生问题。本研究旨在开发一种基于血清 miRNA 的分子特征,用于 NSCLC 的早期检测和预后预测。

方法

在 GSE24709 中分析显著改变的循环 miRNA。上调最明显的前 10 个 miRNA 是 miR-432、miR-942、miR-29c-5p、miR-601、miR-613、miR-520d-3p、miR-1261、miR-132-5p、miR-302b 和 miR-154-5p,而下调最明显的前 10 个 miRNA 是 miR-562、miR-18b、miR-9-3p、miR-154-3p、miR-20b、miR-18a、miR-487a、miR-20a、miR-103 和 miR-144。然后,通过实时定量 PCR 验证前 4 个上调的血清 miRNA(miR-432、miR-942、miR-29c-5p 和 miR-601)。进一步探讨了候选血清 miRNA 两个 miR-942 和 miR-601 的临床意义。

结果

结果显示,血清 miR-942 和血清 miR-601 的表达水平在 NSCLC 中显著上调。此外,血清 miR-942 和血清 miR-601 用于 NSCLC 的早期诊断,其表现优于 CEA、CYFRA21-1 和 SCCA。联合检测血清 miR-942 和血清 miR-601 增强了早期诊断 NSCLC 的效果。此外,高血清 miR-942 和血清 miR-601 均与不良临床变量和预后不良相关。同时高血清 miR-942 和血清 miR-601 的 NSCLC 患者临床结局最差,而同时低血清 miR-942 和血清 miR-601 的患者临床结局最好。多变量分析显示,血清 miR-942 和血清 miR-601 是 NSCLC 的独立预后因素。

结论

总之,血清 miR-942 和血清 miR-601 可能作为 NSCLC 早期检测和预后预测的有前途的分子特征。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/441e/7676218/867ce2be9fc0/JCLA-34-e23505-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/441e/7676218/4c8cf89d5c8f/JCLA-34-e23505-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/441e/7676218/4141d79b9219/JCLA-34-e23505-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/441e/7676218/4c8e0633da49/JCLA-34-e23505-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/441e/7676218/22b7db7173bb/JCLA-34-e23505-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/441e/7676218/867ce2be9fc0/JCLA-34-e23505-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/441e/7676218/4c8cf89d5c8f/JCLA-34-e23505-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/441e/7676218/4141d79b9219/JCLA-34-e23505-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/441e/7676218/4c8e0633da49/JCLA-34-e23505-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/441e/7676218/22b7db7173bb/JCLA-34-e23505-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/441e/7676218/867ce2be9fc0/JCLA-34-e23505-g005.jpg

相似文献

1
A novel circulating miRNA-based signature for the early diagnosis and prognosis prediction of non-small-cell lung cancer.一种新型循环 miRNA 标志物,用于非小细胞肺癌的早期诊断和预后预测。
J Clin Lab Anal. 2020 Nov;34(11):e23505. doi: 10.1002/jcla.23505. Epub 2020 Aug 9.
2
Detection of circulating exosomal miR-17-5p serves as a novel non-invasive diagnostic marker for non-small cell lung cancer patients.循环外泌体 miR-17-5p 的检测可作为非小细胞肺癌患者新型无创诊断标志物。
Pathol Res Pract. 2019 Aug;215(8):152466. doi: 10.1016/j.prp.2019.152466. Epub 2019 May 22.
3
Circulating miRNA panels as a novel non-invasive diagnostic, prognostic, and potential predictive biomarkers in non-small cell lung cancer (NSCLC).循环 miRNA 谱作为一种新型的非侵入性诊断、预后和潜在预测生物标志物在非小细胞肺癌(NSCLC)中的应用。
Br J Cancer. 2024 Nov;131(8):1350-1362. doi: 10.1038/s41416-024-02831-3. Epub 2024 Aug 30.
4
Identification of serum miRNAs by nano-quantum dots microarray as diagnostic biomarkers for early detection of non-small cell lung cancer.通过纳米量子点微阵列鉴定血清微小RNA作为早期检测非小细胞肺癌的诊断生物标志物。
Tumour Biol. 2016 Jun;37(6):7777-84. doi: 10.1007/s13277-015-4608-3. Epub 2015 Dec 22.
5
Serum microRNA Signature Is Capable of Early Diagnosis for Non-Small Cell Lung Cancer.血清 microRNA 特征可用于非小细胞肺癌的早期诊断。
Int J Biol Sci. 2019 Jun 10;15(8):1712-1722. doi: 10.7150/ijbs.33986. eCollection 2019.
6
Serum miR-1228-3p and miR-181a-5p as Noninvasive Biomarkers for Non-Small Cell Lung Cancer Diagnosis and Prognosis.血清 miR-1228-3p 和 miR-181a-5p 作为非小细胞肺癌诊断和预后的非侵入性生物标志物。
Biomed Res Int. 2020 Jul 6;2020:9601876. doi: 10.1155/2020/9601876. eCollection 2020.
7
Identification of differentially expressed circulating serum microRNA for the diagnosis and prognosis of Indian non-small cell lung cancer patients.鉴定用于诊断和预测印度非小细胞肺癌患者的差异表达循环血清 microRNA。
Curr Probl Cancer. 2020 Aug;44(4):100540. doi: 10.1016/j.currproblcancer.2020.100540. Epub 2020 Jan 23.
8
Clinical evaluation of microRNA expression profiling in non small cell lung cancer.非小细胞肺癌中 microRNA 表达谱的临床评估。
Lung Cancer. 2013 Sep;81(3):388-396. doi: 10.1016/j.lungcan.2013.05.007. Epub 2013 Jun 10.
9
Circulating exosomal microRNAs as prognostic biomarkers for non-small-cell lung cancer.循环外泌体微小RNA作为非小细胞肺癌的预后生物标志物
Oncotarget. 2017 Feb 21;8(8):13048-13058. doi: 10.18632/oncotarget.14369.
10
Serum miR-339-3p as a potential diagnostic marker for non-small cell lung cancer.血清 miR-339-3p 作为非小细胞肺癌的潜在诊断标志物。
Cancer Biol Med. 2020 Aug 15;17(3):652-663. doi: 10.20892/j.issn.2095-3941.2020.0063.

引用本文的文献

1
The Role of microRNAs in Lung Cancer: Mechanisms, Diagnostics and Therapeutic Potential.微小RNA在肺癌中的作用:机制、诊断及治疗潜力
Int J Mol Sci. 2025 Apr 15;26(8):3736. doi: 10.3390/ijms26083736.
2
Epigenetic modifications in early stage lung cancer: pathogenesis, biomarkers, and early diagnosis.早期肺癌中的表观遗传修饰:发病机制、生物标志物与早期诊断
MedComm (2020). 2025 Feb 21;6(3):e70080. doi: 10.1002/mco2.70080. eCollection 2025 Mar.
3
[Predictive Value of A miRNA Signature for Distant Metastasis in Lung Cancer].[一种miRNA特征对肺癌远处转移的预测价值]

本文引用的文献

1
Serum exosomal miR-378 upregulation is associated with poor prognosis in non-small-cell lung cancer patients.血清外泌体 miR-378 上调与非小细胞肺癌患者预后不良相关。
J Clin Lab Anal. 2020 Jun;34(6):e23237. doi: 10.1002/jcla.23237. Epub 2020 Feb 14.
2
miR-601 inhibits proliferation, migration and invasion of prostate cancer stem cells by targeting KRT5 to inactivate the Wnt signaling pathway.微小RNA-601通过靶向角蛋白5使Wnt信号通路失活,从而抑制前列腺癌干细胞的增殖、迁移和侵袭。
Int J Clin Exp Pathol. 2019 Dec 1;12(12):4361-4379. eCollection 2019.
3
MiR-942 regulates the function of breast cancer cell by targeting FOXA2.
Zhongguo Fei Ai Za Zhi. 2024 Dec 20;27(12):919-930. doi: 10.3779/j.issn.1009-3419.2024.102.43.
4
Exosomal microRNAs in lung cancer: a narrative review.肺癌中的外泌体微小RNA:一篇叙述性综述。
Transl Cancer Res. 2024 Jun 30;13(6):3090-3105. doi: 10.21037/tcr-23-2319. Epub 2024 Jun 13.
5
MiRNAs and Microbiota in Non-Small Cell Lung Cancer (NSCLC): Implications in Pathogenesis and Potential Role in Predicting Response to ICI Treatment.miRNAs 与非小细胞肺癌(NSCLC)中的微生物群:在发病机制中的意义及在预测 ICI 治疗反应中的潜在作用。
Int J Mol Sci. 2024 Jun 18;25(12):6685. doi: 10.3390/ijms25126685.
6
Pancreatic Neuroendocrine Tumors: Signaling Pathways and Epigenetic Regulation.胰腺神经内分泌肿瘤:信号通路与表观遗传调控
Int J Mol Sci. 2024 Jan 22;25(2):1331. doi: 10.3390/ijms25021331.
7
Serum Insights: Leveraging the Power of miRNA Profiling as an Early Diagnostic Tool for Non-Small Cell Lung Cancer.血清洞察:利用微小RNA谱分析的力量作为非小细胞肺癌的早期诊断工具。
Cancers (Basel). 2023 Oct 10;15(20):4910. doi: 10.3390/cancers15204910.
8
Exploring the Potential of Non-Coding RNAs as Liquid Biopsy Biomarkers for Lung Cancer Screening: A Literature Review.探索非编码RNA作为肺癌筛查液体活检生物标志物的潜力:文献综述
Cancers (Basel). 2023 Sep 28;15(19):4774. doi: 10.3390/cancers15194774.
9
Extracellular circulating miRNAs as potential non-invasive biomarkers in non-small cell lung cancer patients.细胞外循环微小RNA作为非小细胞肺癌患者潜在的无创生物标志物
Front Oncol. 2023 Jul 21;13:1209299. doi: 10.3389/fonc.2023.1209299. eCollection 2023.
10
Circulating noncoding RNAs: promising biomarkers in liquid biopsy for the diagnosis, prognosis, and therapy of NSCLC.循环非编码RNA:液体活检中用于非小细胞肺癌诊断、预后和治疗的有前景的生物标志物。
Discov Oncol. 2023 Aug 1;14(1):142. doi: 10.1007/s12672-023-00686-3.
miR-942 通过靶向 FOXA2 调节乳腺癌细胞的功能。
Biosci Rep. 2019 Nov 29;39(11). doi: 10.1042/BSR20192298.
4
miR-942 promotes proliferation and metastasis of hepatocellular carcinoma cells by inhibiting RRM2B.微小RNA-942通过抑制核糖核苷酸还原酶M2B亚基促进肝癌细胞的增殖和转移。
Onco Targets Ther. 2019 Oct 11;12:8367-8378. doi: 10.2147/OTT.S207549. eCollection 2019.
5
miR-942 promotes tumor migration, invasion, and angiogenesis by regulating EMT via BARX2 in non-small-cell lung cancer.miR-942 通过调节 BARX2 促进非小细胞肺癌中的 EMT 来促进肿瘤迁移、侵袭和血管生成。
J Cell Physiol. 2019 Dec;234(12):23596-23607. doi: 10.1002/jcp.28928. Epub 2019 Jun 24.
6
Circulating microRNA array (miR-182, 200b and 205) for the early diagnosis and poor prognosis predictor of non-small cell lung cancer.循环 microRNA 阵列(miR-182、200b 和 205)用于非小细胞肺癌的早期诊断和不良预后预测。
Eur Rev Med Pharmacol Sci. 2019 Feb;23(3):1108-1115. doi: 10.26355/eurrev_201902_17001.
7
MiR-601 inhibits the proliferation and metastasis of esophageal squamous cell carcinoma (ESCC) by targeting HDAC6.miR-601 通过靶向 HDAC6 抑制食管鳞癌(ESCC)的增殖和转移。
Eur Rev Med Pharmacol Sci. 2019 Feb;23(3):1069-1076. doi: 10.26355/eurrev_201902_16995.
8
Cancer statistics, 2019.癌症统计数据,2019 年。
CA Cancer J Clin. 2019 Jan;69(1):7-34. doi: 10.3322/caac.21551. Epub 2019 Jan 8.
9
MicroRNA Expression Profiles in Gastric Carcinogenesis.胃肿瘤发生过程中的 microRNA 表达谱。
Sci Rep. 2018 Sep 26;8(1):14393. doi: 10.1038/s41598-018-32782-8.
10
A three miRNAs signature for predicting the transformation of oral leukoplakia to oral squamous cell carcinoma.一种用于预测口腔白斑向口腔鳞状细胞癌转变的三联体微小RNA特征。
Am J Cancer Res. 2018 Aug 1;8(8):1403-1413. eCollection 2018.